JP2017531699A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531699A5
JP2017531699A5 JP2017540976A JP2017540976A JP2017531699A5 JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5 JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5
Authority
JP
Japan
Prior art keywords
dose
hpv
use according
vaccine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531699A (ja
JP6663438B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/057150 external-priority patent/WO2016065281A1/en
Publication of JP2017531699A publication Critical patent/JP2017531699A/ja
Publication of JP2017531699A5 publication Critical patent/JP2017531699A5/ja
Application granted granted Critical
Publication of JP6663438B2 publication Critical patent/JP6663438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540976A 2014-10-24 2015-10-23 癌および皮膚病変の治療 Active JP6663438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
US62/068,332 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (3)

Publication Number Publication Date
JP2017531699A JP2017531699A (ja) 2017-10-26
JP2017531699A5 true JP2017531699A5 (https=) 2018-11-15
JP6663438B2 JP6663438B2 (ja) 2020-03-11

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540976A Active JP6663438B2 (ja) 2014-10-24 2015-10-23 癌および皮膚病変の治療

Country Status (15)

Country Link
US (1) US10238729B2 (https=)
EP (1) EP3209676A4 (https=)
JP (1) JP6663438B2 (https=)
KR (1) KR102285401B1 (https=)
CN (1) CN107001430A (https=)
AU (1) AU2015335652B2 (https=)
BR (1) BR112017008280A2 (https=)
CA (1) CA2965498A1 (https=)
CL (1) CL2017001008A1 (https=)
IL (1) IL251825B2 (https=)
MX (1) MX395186B (https=)
MY (1) MY195018A (https=)
PH (1) PH12017500754A1 (https=)
SG (1) SG11201703262UA (https=)
WO (1) WO2016065281A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506435A (ja) * 2016-02-27 2019-03-07 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. ワクチンを使用して癌または皮膚病変を治療するための方法および組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
WO2004056389A1 (en) 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
EP3427755B1 (en) * 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
US9566323B2 (en) 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
SG177269A1 (en) * 2009-06-25 2012-02-28 Glaxosmithkline Biolog Sa Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US20150086587A1 (en) * 2012-03-28 2015-03-26 Kansas State University Research Foundation Vaccine adjuvant
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9974849B2 (en) 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine

Similar Documents

Publication Publication Date Title
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
Abeck et al. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children
Ma et al. Emerging human papillomavirus vaccines
Lin et al. Therapeutic hpv DNA vaccines
JP2016537417A5 (https=)
JP2017502081A5 (https=)
JP2010530362A5 (https=)
Tran et al. Spontaneous regression of metastatic melanoma after inoculation with tetanus–diphtheria–pertussis vaccine
JP2019531293A5 (https=)
JP7460094B2 (ja) 子宮頸がんの治療方法
Devaraja Current prospects of molecular therapeutics in head and neck squamous cell carcinoma
Ding et al. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer
Perez‑Trujillo et al. DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect
JP2018509423A5 (https=)
CN119770632A (zh) 诱导免疫应答的组合物和方法
JP2017531699A5 (https=)
JP6663438B2 (ja) 癌および皮膚病変の治療
Wang et al. The role and development of peptide vaccines in cervical cancer treatment
EP4196157A1 (en) Compositions for treating gastrointestinal adenocarcinomas by altering the tumor microenvironment
RU2832963C2 (ru) Способ лечения рака шейки матки
HK1241898A1 (en) Cancer and skin lesion treatment
Kumar et al. The Current Landscape for Human Papillomavirus Vaccination in Oropharyngeal Carcinoma
Melief Peptide-based therapeutic cancer vaccines
Aremu et al. Immunotherapy for head and neck cancers
Alfonso et al. Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16